Source: VIP Gloves
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • VIP Gloves (VIP) receives Australian Therapeutic Goods Administration (TGA) approval for its nitrile gloves
  • The TGA has registered VIP’s nitrile examination and treatment gloves as a class one medical device and has given approval to sell the gloves in Australia
  • This news follows USA Food and Drug Administration and European Union CE Mark approvals
  • VIP is up 7.50 per cent and is trading at 4.3 cents per share at 2:25 pm AEST

VIP Gloves (VIP) has received Australian Therapeutic Goods Administration (TGA) approval for its nitrile gloves.

Nitrile gloves are a synthetic rubber compound as opposed to latex.

The TGA has registered VIP’s nitrile examination and treatment gloves as a class one medical device and has given approval to sell the gloves in Australia.

This news follows USA Food and Drug Administration and European Union CE Mark approvals.

Chairman Joe Wong is pleased to have secured TGA approval.

“We have been advancing distribution agreements for the Australian
market in recent months and, with TGA accreditation now received, these
can be finalised enabling sales to commence in the coming months,” Dr Wong said.

“VIP Gloves continues to expand its international sales footprint to become
a global glove supplier, providing a platform to launch the company’s house
brands as capacity expands in the coming months when the additional two
production lines come online.”

VIP was up 7.50 per cent and was trading at 4.3 cents per share at 2:25 pm AEST.

VIP by the numbers
More From The Market Online
The Market Online Video

Listen: From the Wire – Paradigm Biopharma CEO and Founder Paul Rennie

From The Wire: Senior markets reporter Jonathon Davidson sat down with Paradigm Biopharmaceuticals chief executive officer…
Lung imaging concept

Biotech lung imaging darling 4DX Medical back at $2.20/sh on Miami U contract

4DX Medical has seen its price jump back to $2.20/sh, as its next-gen lung imaging scan…
Chuffed bloke

Race Oncology’s placement-at-a-premium rewarded as shares jump +8%

Race Oncology has completed its recent A$3.2M placement – something that shareholders on the HotCopper forums…

Effective as an IV drug, a gel, and now an inhaler – Recce’s R327 can’t stop winning

Recce flagship antibacertial and anti-infective drug R327 has in a model that shows the drug could…